Vera Therapeutics CEO Disposes of $1.01 Million in Stock as Company Nears Key Milestones
Marshall Fordyce, President and CEO of Vera Therapeutics, sold 22,951 shares of Class A common stock on April 14, 2026, in transactions executed under a pre-arranged 10b5-1 plan adopted January 9, 2026. The sales totaled $1,011,050 across multiple price points. The company has attracted recent analyst attention and made executive and board appointm…